Biotech stories
AI specialists are still a minority, but their rapid sales growth signals Britain's scale-up market is broadening beyond traditional sectors.
The move gives the campus its first commercial occupier for The Sequence and adds 21,000 sq ft of labs for health start-ups.
The advisory body is meant to steer an expanded Cambridge site aiming to house 9,000 people and about 250 life sciences companies by 2028.
Five days of talks in Cambridge will focus on how deep tech can scale internationally, with energy, AI and investment leaders set to attend.
Artificial intelligence has become the main driver of UK tech value, with venture funding and start-up creation increasingly concentrated in the sector.
The funding will help London-based Apoha commercialise a liquid data layer already used by Boehringer Ingelheim and other pharma groups.
European firms needing secure, low-carbon compute gain a bigger home as the deal expands cloud, AI and dedicated HPC services under one roof.
Food and agriculture start-ups may see fresh capital as the firm targets software and biology plays after the sector's sharp funding pullback.
Eligible research organisations can now access OpenAI's updated GPT-Rosalind model, as the company widens its life sciences rollout worldwide.
The platform targets manual drug-development bottlenecks, from trial documents to safety case intake, as biopharma seeks faster compliant workflows.
The new specialisation should help healthcare and life sciences firms use governed AI and data tools to speed trials, discovery and patient insights.
AI in life sciences is boosting workflows rather than replacing scientists, as firms navigate regulation, data risks and uneven adoption across markets.
Life sciences firms could avoid costly FDA review delays as the software flags conflicting claims across filings before submissions are sent.
Most fintech startups could miss out on planned tax relief unless Treasury rewrites rules to reflect the sector's long, costly path to scale.
Recruitment delays at Canopy's sites could ease as a dedicated platform is set to cut missed follow-ups and lift enrolment rates.
Healthcare and AI start-ups dominate the shortlist, as investors prepare to hear pitches from firms tackling accessibility, childcare and drug delivery.
Investor demand for Australian startups is outpacing funding channels, with only 27% willing to commit more than AUD $100,000 to one deal.
The hub's second year delivered a 21% rise in output, with independent analysis showing it supported 148 jobs across Wellington.
Access gaps, not investor appetite, are holding back Australian innovation funding despite 66% already backing startups and new businesses.
The grants are set to speed the rollout of AI tools across healthcare, manufacturing and finance, helping GTA firms reach market sooner.